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Abstract. The aim of the present study was to describe a rare 
case of orbital precursor B-lymphoblastic lymphoma (B-LBL) 
in an adult. A 56-year-old male in complete remission of a 
gastric precursor B-LBL was referred to our orbital clinic 
due to rapid development of left-sided painless periorbital 
swelling, diplopia, and proptosis. Complete ophthalmoplegia 
was observed. Notably, magnetic resonance imaging showed 
swelling of the medial and inferior rectus muscles in the left 
orbit and biopsies were performed. Following histological 
diagnosis of precursor B-LBL, the patient was treated with 
radiotherapy (2Gy x 20) and chemotherapy according to the 
NOPHO ALL 2008 protocol. The disease progressed and 
the patient succumbed after 5 months. Histomorphologically, 
a lymphoblastic infiltrate was observed within the skeletal 
muscle tissue. The tumor cells were small and immature, and 
stained strongly for cluster of differentiating (CD)10, CD79a, 
paired box 5 and B cell lymphoma-2. The Ki-67 proliferative 
index was 90%. Multiplex ligation‑dependent probe amplifica-
tion and array comparative genomic hybridization detected 
whole chromosomal gain of X and 12, and both hemizygous 
and homozygous deletion on 9p comprising cyclin depen-
dent kinase inhibitor 2A/B. Furthermore, array comparative 
genomic hybridization detected copy number imbalances 
consisting of focal or smaller deletions on chromosomes 1, 
9, 10, 11 and 20. The final diagnosis was precursor B‑LBL 
relapse in the extraocular muscles. Orbital precursor B-LBL is 
extremely rare in adults, and the diagnosis may be challenging 
to make. It is recommended to obtain material for cytogenetic 
and molecular analyses.
Introduction
Precursor B-lymphoblastic lymphoma (B-LBL) is a rare 
and highly aggressive malignant neoplasm of lymphoblasts 
committed to the B-cell lineage, primarily presenting as 
extranodal tumors and with low propensity for leukemic 
involvement in children and young adults (1). B-LBL is an 
uncommon subtype of ocular adnexal lymphoma (OAL), with 
only nine published orbital cases (Table I). Of the previous 
cases, one occurred in an infant (2), five in children (3-7), 
and two in young adults (6). OAL is the most frequent orbital 
malignancy in adults (6); however, extraocular muscle involve-
ment is uncommon. In 2011, Watkins et al (8) published a 
major review of lymphoid tumors in extraocular muscles, 
identifying 57 cases comprising 0.17% of all OAL. Since then, 
eight additional cases have been published (9-12). So far, none 
of the reported cases presented as B-LBL.
We present the first case of B‑LBL with extraocular 
muscle involvement. The patient is older than the normal age 
range for this disease and showed intermittent orbital symp-
toms initially undetectable by magnetic resonance imaging 
(MRI). The aim of this study was to present the clinical, 
histopathological, and genetic characteristics of this rare 
condition.
Materials and methods
Clinical course. A 56-year-old Caucasian male was in complete 
remission of a histopathologically confirmed precursor B‑LBL 
in the abdomen treated with chemotherapy (Hyper-CVAD) 
according to the MD Anderson recommendations (13). 
Remission was confirmed by whole body positron emission 
tomography-computerized tomography (PET-CT) and CT of 
the abdomen. At this time, flow cytometry of a bone marrow 
biopsy showed many suspected malignant CD10 and CD19 
positive cells from the B-cell lineage, representing immature 
B-cells.
Three months later, the patient experienced a sudden onset 
of left-sided droopy eyelid and diplopia without pain for a few 
days. These symptoms disappeared spontaneously and the 
neurological examination was unremarkable. MRI of the orbit 
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did not detect a mass lesion and ophthalmological examination 
was normal.
Another 2 months later, the symptoms reoccurred with 
marked periorbital swelling, blepharoptosis, diplopia, and 
slight proptosis of the left eye without pain. Both MRI of 
the orbit and PET were again normal and the patient was 
referred to our tertiary orbital clinic. On examination, left 
axial proptosis (Hertel 22/26 mm) and partial left‑side third 
nerve palsy was noted. Visual acuity (VA) was 6/6 in both 
eyes. Color vision, pupil response, and visual field investiga-
tion were all normal. However, during the following 5 days, 
rapidly developing pain, decreased visual acuity of the left 
eye (6/12), chemosis, increasing proptosis (22/27 mm), and 
total ophthalmoplegia (frozen socket) ensued. Mydriasis 
developed, but no afferent pupillary (RAPD) defect was 
present. MRI showed thickening of the medial and inferior 
rectus muscles with very subtle ‘dirty fat’, suggesting an 
infiltrative lesion (Fig. 1A). Orbital biopsies were obtained 
through an anterior orbitotomy. The patient had no light 
perception the day after surgery. A blood test performed at 
the time of orbital involvement was normal with no blasts. 
At diagnosis, repeated bone marrow biopsies showed no 
systemic involvement. Chemotherapy according to the 
high‑risk NOPHO ALL 2008 protocol (14) and orbital radia-
tion (2Gy x 20) was initiated and myeloablative allogeneic 
bone marrow transplantation was planned.
One month postoperatively, the orbital swelling diminished 
and some abduction was noted. However, the patient's condi-
tion quickly deteriorated to a degree where treatment was not 
tolerated. A bone marrow biopsy at this time revealed systemic 
involvement with numerous blasts present. The patient ceased 
before transplantation was performed.
The patient has given his informed consent to publication. 
The present study adheres to the declaration of Helsinki, and 
was approved by the local ethics committee (H-B-2009-054).
Histopathology and immunohistochemistry. A biopsy from 
the inferior rectus muscle of the left orbit was obtained for 
histological examination. The specimen was fixed in 10% 
formalin and embedded in paraffin immediately after surgical 
excision. Sections (2 µm) were prepared and stained with 
hematoxylin and eosin according to standard protocols. 
Furthermore, sections were stained with periodic acid Schiff 
(PAS), Gram, Gomori methenamin silver stain, and Giemsa 
also in line with standard protocols.
Immunohistochemical stainings were performed on a 
Ventana BenchMark ULTRA Platform (Ventana Medical 
Systems, Tucson, AZ, USA) as previously described (15). 
The following antibodies were used: Cluster of differentia-
tion (CD) 3 (clone 2GV6, code 790-4341, rabbit anti-human, 
Ready‑to‑use (RTU); Roche, Hvidovre, Denmark), CD10 (clone 
SP 67, code 790-4506, rabbit anti-human, RTU; Roche), CD20 
(clone L26, code 760-2531, mouse anti-human, RTU; Roche), 
CD34 (clone QBEnd/10, code 790‑2927, mouse anti‑human, 
RTU; Roche), CD79a (clone SP18, code 790-4432, rabbit 
anti-human, RTU; Roche), BCL-2 (clone 124, code 790-4464, 
mouse anti‑human, RTU; Roche), BCL6 (clone GI1E/A8, code 
760-4241, mouse anti-human, RTU; Roche), MPO (polyclonal, 
code A0398, rabbit anti‑human, 1:2,000; Dako; Agilent 
Technologies, Inc., Santa Clara, CA, USA), PAX‑5 (clone 
SP34, code 790-4420, rabbit anti-human, RTU; Roche), TdT 
(clone SEN28, code NCL-TdT-339, mouse anti-human, 1:100; 
Novocastra, Brønshøj, Denmark), Vimentin (clone V9, code 
790‑2917, mouse anti‑human, RTU; Roche), and KI‑67 (clone 
MIB‑1, code M724001, mouse anti‑human, 1:100; Dako; 
Agilent Technologies, Inc.). Positive and negative controls 
were performed according to the manufacturers' instructions.
Genetics. After dissecting the tumor sample, genomic DNA 
and RNA were extracted using QIAamp DNA Mini kit 
(Qiagen GmbH, Hilden, Germany).
Multiplex ligation‑dependent probe amplification. Multiplex 
ligation‑dependent probe amplification (MLPA) was performed 
on DNA using the SALSA MLPA kit P335‑A1 according to 
manufacturer's instructions (MRC Holland, Amsterdam, the 
Netherlands). The analysis is suited for the detection of copy 
number variations in the following genes: IKZF1, CDKN2A/B, 
PAX5, EBF1, ETV6, RB1, BTG1, RB1, and the PAR1 region: 
CRLF2, CSF2A, IL3A.
Array CGH. Genome-wide array CGH analysis (array CGH) 
was performed on DNA using the Agilent SurePrint G3 
Human CGH Microarray kit 2x400K (Agilent Technologies, 
Inc.). Labeling and hybridization were performed according to 
the protocol provided by Agilent Technologies, Inc., (protocol 
v6.0, November 2008) as previously described (16).
Multiplex RT‑PCR. Multiplex RT-PCR was performed 
on cDNA synthesized from tumor RNA according to 
the HemaVision-28N protocol (HemaVision-28N, Cat. 
No. HV01‑28N, DNA Diagnostic, Risskov, Denmark). The 
analysis screens for 28 chromosomal translocations, including 
the most common ALL related translocations.
Fluorescent in situ hybridization (FISH). Fluorescent in situ 
hybridization (FISH) was performed using the probes for 
BCR-ABL (cat. no: 05J90-001; Abbott Molecular, Emdrup, 
Denmark), ETV‑6 (cat. no: Z‑2176; ZytoVision GmbH, 
Bremerhaven, Germany), and MLL (KMT2A) (cat. no: Z-2111; 
ZytoVision) according to the manufacturers' protocol using the 
HyBrite platform (Abbott Molecular). After hybridization, the 
nuclei were counterstained with DAPI II (ZytoVision). One 
hundred nuclei were counted and the cut-off was set to 10%.
Flow cytometry. The BM sample was processed and stained 
for flow cytometric immunophenotyping with standard proce-
dures according to the NOPHO acute lymphoblastic leukemia 
guidelines (17). Data acquisition was performed on a BD 
FACSCanto II (BD Biosciences, San José, CA, USA) according 
to manufacturer's instructions. An antibody combination of 
CD3 (clone: G4.18, cat. no: 554829, RTU; BD Biosciences), 
CD4 (clone: SK3, cat. no: 651949, RTU; BD Biosciences), CD5 
(clone: L17F12, cat. no: 341109, RTU; BD Biosciences), CD8 
(clone: SK1, cat. no: 345772, RTU; BD Biosciences), CD10 
(clone: ALB1, cat. no: IM1915u, RTU; Beckman Coultier, 
Copenhagen, Denmark), CD19 (clone: SJ25C1, cat. no: 341113, 
RTU; BD Biosciences), CD20 (clone: L27, cat. no: 655872, 
RTU; BD Biosciences), CD23 (clone: MHM6, cat. no: F7062, 
RTU; Dako; Agilent Technologies, Inc.), CD34 (clone: 581, 
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cat. no: A89309, RTU; Beckman Coultier), CD38 (clone: HB7, 
cat. no: 345807, RTU; BD Biosciences), CD45 (clone: 2D1, cat. 
no: 655873, RTU; BD Biosciences), CD56 (clone: NCAM 16.2, 
cat. no: 345812, RTU; BD Biosciences), CD79b (clone: SN8, 
cat. no: 335834, RTU; BD Biosciences), CD200 (clone: OX104, 
cat. no: 17-9200-41, RTU, eBioscience, Thermo Fischer 
Scientific, Roskilde, Denmark), kappa light chain (Polyclonal, 
cat. no: R0436, RTU; Dako; Agilent Technologies, Inc.), and 
lambda light chain (Polyclonal, cat. no: F0435, RTU; Dako; 
Agilent Technologies, Inc.), were used. Data was analyzed 
using FlowJo 9.3.1 software (FlowJo LLC, Ashland, OR, USA) 
according to the NOPHO protocol (17).
Results
Histopathology and immunohistochemistry. An infiltrate 
of immature lymphoblastic cells was seen within the orbital 
skeletal muscle tissue (Fig. 1B). The tumor cells were small and 
presented with fine blastic nuclear chromatin along with small 
peripheral nucleoli (Fig. 1C). The tumor cells stained positively 
for PAX-5 (Fig. 1D) CD10, CD79a, and BCL-2. Staining for 
CD3, CD20, CD34, TdT, BCL6, and MPO was negative. The 
Ki-67 proliferation index was very high, approximately 90% 
(Fig. 1E). These findings resembled the primary abdominal 
biopsy and were consistent with a TdT-negative precursor 
B-LBL relapse.
Biopsies obtained from the orbital soft tissue contained 
no tumor cells, indicating that the tumor was confined to the 
orbital muscles.
Flow cytometry. Flow cytometry of a bone marrow biopsy 
performed at the time of first presentation identified 
numerous monoclonal immature blasts from the B-cell lineage 
(Fig. 2).
Genetics. FISH analyses were negative for rearrangement of 
ETV6, KMT2A (formerly MLL), and BCR/ABL.
MLPA and array CGH analyses detected whole chromo-
somal gain of X and 12 and both hemizygous and homozygous 
deletion on 9p comprising CDKN2A/B (deletions ranging from 
21,323,778-30,864,756 bp; Fig. 3). Array CGH showed that the 
pattern of deletions was complex, with homozygous deletions 
flanked by hemizygously deleted regions (Fig. 4).
Furthermore, array CGH detected copy number imbal-
ances consisting of focal or smaller deletions on chromosomes 
1, 9, 10, 11, and 20 (Table II).
No leukemia‑associated translocations were identified 
when screening for 28 chromosomal translocations by multi-
plex RT-PCR.
Discussion
The present study presents the first case of B‑LBL of the orbit 
involving the extraocular muscles in a 56-year-old male.
Precursor B-LBL has a male predilection, is primarily a 
disease of children and young adults, and the clinical course 
is usually characterized by rapid growth of a mass involving 
lymph nodes, skin, bone, or other extranodal sites. The prog-
nosis is favorable, with a survival rate of approximately 90% in 
Table I. Cases of biopsy‑proven orbital precursor‑lymphoblastic lymphoma/acute lymphoblastic leukemia reported in the 
literature.
 Age Primary Sex
Author (year) (years) lesion m/f Location Treatment Prognosis (Refs.)
Thakker et al (2006) <1 Yes F Right orbit NOPHO Alive 1 year (2)
      without relapse
Chou et al (2005) 6 No M Left orbit RT and Alive 4 years (3)
     chemotherapy without relapse
Alford et al (1999) 12 Yes M Left orbit RT and Multiple relapses, (4)
     chemotherapy alive 4 years
     and ASCT after last relapse
Faridpooya et al (2009) 6 Yes M Left orbit Chemotherapy Alive 19 years (5)
      without relapse
Ferry et al (2007) 7 Yes F Left orbit N/A N/A (6)
Ferry et al (2007) 38 Yes F Left orbit N/A N/A (6)
Ferry et al (2007) 45 Yes F Right orbit N/A N/A (6)
Ramamoorthy 4 No F Left orbit Chemotherapy Alive 6 months (7)
et al (2016)      without relapse
Present case 56 No M Left orbit, RT and Died after -
    extraocular NOPHO 3 months
    muscles
M, male; F, female; RT, radiotherapy; ASCT, allogenic stem cell transplantation.
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children, but outcome worsens with age (1), as the present case 
illustrates. In addition, patients with relapsed disease have a poor 
outcome (18). This is the oldest patient described with orbital 
B-LBL and a corresponding aggressive clinical course. Despite 
appropriate treatment with orbital radiotherapy and multi-agent 
chemotherapy according to high‑risk NOPHO regimen (12), the 
disease was refractory and the patient died. Eight previously 
reported cases of biopsy-proven orbital B-LBL are summarized 
in Table I. B‑LBL and B‑acute lymphoblastic leukemia (ALL) 
are considered the same disease spectrum, distinguished by the 
degree of bone marrow involvement (1). Whereas extraocular 
muscle involvement of an orbital T-lymphoblastic lymphoma 
has recently been described (12), this is the first reported case 
with primarily extraocular muscle involvement of B-LBL. Thus, 
representing a rare manifestation of orbital lymphoma, this case 
highlights the importance of ensuring an accurate diagnosis by 
means of an orbital biopsy, including the extraocular muscles if 
indicated by imaging. Indeed, the extramuscular orbital biopsy 
was devoid of lymphoblasts, which were only confirmed in the 
extraocular muscles.
The histopathological diagnosis of a highly aggressive 
orbital B-LBL may be challenging and may lead to delayed 
initiation of the correct therapy. The immature tumor cells 
may present with slightly different morphology and immu-
nohistochemistry may not always be conclusive. A positive 
staining for TdT is usually suggestive for the diagnosis of 
ALL/LBL, but in the present case this staining was negative. 
Interestingly, a case of a TdT‑negative orbital T‑LBL with 
muscle involvement has previously been described (12).
Molecular techniques are needed to make a genetic diag-
nosis allowing for more precise characterization of the tumor 
in case of diagnostic uncertainty. The eye pathologist should 
preferably obtain unfixed material for this purpose. In the 
present case, array CGH, FISH, and MLPA were performed. 
The tumor had an unstable genome with whole chromosomal 
gain of X and 12, and focal or smaller deletions were found 
on chromosomes 1, 9, 10, 11, and 20. Furthermore, both 
hemizygous and homozygous deletion on 9p, comprising 
CDKN2A/B was detected. Several cytogenetic abnormalities 
have been identified in B‑LBL, and these are highly valu-
able in the prognostication of paediatric disease (19). In 
contrast, adult cases have not been studied in detail, and 
good prognostic features such as hyperdiploidy with 51-65 
chromosomes and the translocation t(12;21) are infrequent. 
Whole chromosomal gain of the sex chromosomes has been 
shown to be common in adult pre-B ALL, and deletions 
of CDKN2A/B are highly characteristic of LBL/ALL in 
all age groups in hemizygous and homozygous forms (20). 
Inactivation of the tumor suppressor genes, CDKN2A/B, is 
associated with a poor outcome in all B-LBL patients (21). 
This is in line with the poor outcome in our case. In adult 
B-LBL, the poor prognostic translocation t(9;22)(q34;q11.2) 
(BCR/ABL) is found in 25% of cases (19), however, this was 
not present in our case.
As the present case illustrates, patients with relapsed 
B-LBL or presentation at a higher age have a poor prognosis. 
Figure 1. Magnetic resonance imaging and histopathological analysis of 
orbital B-LBL. (A) Magnetic resonance imaging showed swelling of the left 
inferior and medial rectus muscles (arrow) and a biopsy was performed. (B) A 
neoplastic infiltrate was found within the skeletal muscle tissue (hematoxylin 
and eosin; bar=100 µm). (C) The small tumor cells had a blastic morphology 
and surrounded the myocytes (asterisk). The cytoplasm was scant and 
the nucleoli had a fine chromatin (hematoxylin and eosin; bar=40 µm). 
(D) The tumor cells were positive when stained for the pan‑B‑cell marker 
PAX-5 (bar=50 µm). (E) The proliferative index measured with Ki-67 was 
approximately 90% (bar=70 µm). B-LBL, B-lymphoblastic lymphoma.
Table II. Imbalances detected by array comparative genomic 
hybridization.
Chromosome Position (bp) Gain/loss
  1 188,838,117-190,329,277 Hemizygous loss
  1 214,360,104-214,736,822 Hemizygous loss
  1 232,437,508-236,208,925 Hemizygous loss
  9 10,631,808-15,671,229 Hemizygous loss
  9 21,323,778-21,885,253 Hemizygous loss
  9 21,901,322-22,032,716 Homozygous loss
  9 22,036,446-22,365,771 Hemizygous loss
  9 22,382,290-22,583,476 Homozygous loss
  9 22,592,720-26,554,414 Hemizygous loss
  9 26,576,505-26,746,962 Homozygous loss
  9 26,760,476-30,864,756 Hemizygous loss
  9 75,777,676-79,018,498 Hemizygous loss
10 9,551,403-11,770,319 Hemizygous loss
10 37,205,162-37,826,531 Hemizygous loss
11 6,550,803-6,632,573 Hemizygous loss
11 6,639,238-6,665,699 Homozygous loss
11 6,669,807-6,724,677 Hemizygous loss
12 pter-qter Gain
20 57,595,945-58,000,098 Hemizygous loss
X pter-qter Gain
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Figure 2. Flow cytometry of B‑cells from a bone marrow biopsy at the time when gastric B‑LBL was diagnosed demonstrating a kappa‑chain restriction 
along with many CD19+ and CD10+ cells. These cells represent monoclonal immature B-cells characteristic for precursor B-LBL. B-LBL, B-lymphoblastic 
lymphoma.
Figure 3. MLPA shows gain of chromosomes 12 and X and homozygous deletion of an area on 9p21, including CDKN2A/B.
Figure 4. Array CGH analysis. (A) Whole chromosome view of chromosome 9 and (B) hemizygous and homozygous CDKN2A/B deletions were observed.
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Accordingly, accurate diagnosis and prompt initiation of treat-
ment adhering to high‑risk protocols are therefore imperative. 
Future studies applying new technologies such as whole 
genome and RNA sequencing may provide new insight into 
the molecular pathways leading to B-LBL.
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